



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 25/00* (2006.01)
C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2021/013136

(22) International Filing Date:

12 January 2021 (12.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

62/960,300	13 January 2020 (13.01.2020)	US
63/024,327	13 May 2020 (13.05.2020)	US
63/092,069	15 October 2020 (15.10.2020)	US
63/122,409	07 December 2020 (07.12.2020)	US

(71) Applicant: **TRUEBINDING, INC.** [US/US]; 1140A O'Brien Drive, Menlo Park, California 94025 (US).

(72) Inventors: **SUN, Dongxu**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **RASOOL, Suhail**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **GORDON, Catherine A.**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **HONG, Ke**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **CHEN, Fan**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **BOLIN, Sara Matilda**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **SHCHORS, Ksenya**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **YU, Yadong**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **TSAL, Tsung-Huang**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **WILLIAMS, Samuel A.F.**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **LALA, Karan**; 1140A O'Brien Drive, Menlo Park,

(54) Title: ANTI-GAL3 ANTIBODIES AND METHODS OF USE



(57) **Abstract:** Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

[Continued on next page]

California 94025 (US). **WU, Heng**; 1140A O'Brien Drive, Menlo Park, California 94025 (US). **WANG, Yan**; 1140A O'Brien Drive, Menlo Park, California 94025 (US).

(74) **Agent: DELANEY, Karoline**; KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
 - *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
 - *with sequence listing part of description (Rule 5.2(a))*
-